|[April 09, 2014]
Research and Markets: PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/tbtbm7/pharmapoint)
has announced the addition of the "PharmaPoint:
Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market
Analysis to 2022" report to their offering.
Similar to the situation in the UK, sales in the Japanese market are
severely constrained by the absence of a routine HBV immunization
program. Furthermore, Japan also does not target adult risk groups for
HBV immunization, an approach that is unique among the eight markets
discussed in this report. Whil Japanese policymakers have hinted at a
more pro-vaccine stance, GlobalData does not expect HBV immunization
recommendations to be expanded in Japan during the forecast period,
which poses a serious barrier to market growth.
Overview of Hepatitis B disease including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on the key drugs in Japan including product
description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Japan from 2012-2022.
Analysis of the impact of key events as well the drivers and
restraints affecting the Japan Hepatitis B disease market.
Key Topics Covered:
Tables & Figures
Vaccination Recommendations and Coverage Rates
Opportunity and Unmet Need
For more information visit http://www.researchandmarkets.com/research/tbtbm7/pharmapoint
[ Back To Cloud Contact Center's Homepage ]